论文部分内容阅读
目的通过分析肾肿瘤中浸润性树突状细胞的免疫状态变化,以探讨其在肾肿瘤微环境中的功能状态。方法选择未经任何非手术治疗的肾透明细胞癌患者标本40例作为实验组,10例正常肾组织作为对照组,通过免疫组织化学技术标记组织中树突状细胞(dendritic cell,DC)的CD1a、HLA-DR和CD86抗原,观察正常肾及肾透明细胞癌组织中DC的3种抗原的表达,结果进行统计学分析。结果所有肾透明细胞癌组织中均未见明显CD86+DC,但均有CD1a+DC,其在肾癌组织中的浸润程度明显高于正常肾组织(P<0.001),但CD1a+DC与肾癌临床分期及组织学分级均无相关性;在肾癌组中有34例癌实质内的DC表达HLA-DR抗原,其阳性表达率为85%,与正常肾组织80%的阳性表达率相比无统计学意义(P>0.05)。结论DC具有趋化性,可以向肿瘤组织聚集,肾癌组织中存在CD1a,肾癌患者CD86表达低下,提示肾癌患者DC存在免疫缺陷,而DC的免疫功能低下则可能是肾癌逃避宿主免疫监视的主要原因。
OBJECTIVE: To investigate the immunological status of infiltrating dendritic cells in kidney neoplasms to investigate their functional status in renal tumor microenvironment. Methods 40 cases of renal clear cell carcinoma without any non-surgical treatment were selected as experimental group and 10 cases of normal renal tissue as control group. The expression of CD1a in dendritic cells (DCs) was detected by immunohistochemistry , HLA-DR and CD86 antigens, and to observe the expression of three antigens of DC in normal kidney and renal clear cell carcinoma. The results were statistically analyzed. Results No clear CD86 + DC was found in all clear cell renal cell carcinoma, but all had CD1a + DC. The infiltration of CD1a + DC in renal cell carcinoma was significantly higher than that in normal renal tissue (P <0.001) Cancer clinical stage and histological grade were no correlation; in the group of renal cell carcinoma, 34 cases of DC within the cancerous parenchyma expression of HLA-DR antigen, the positive expression rate was 85%, and 80% of normal renal tissue positive expression rate No significant difference (P> 0.05). Conclusions DCs are chemotactic and can accumulate in tumor tissues. CD1a is present in renal cell carcinoma and CD86 is low in renal cell carcinoma patients, suggesting that DCs in renal cell carcinoma may be immunodeficient. DC immunosuppression may be the result of immune escape from host immune system The main reason for monitoring.